Want to see ICU full AI Analyst Report?
ICU Stock Chart & Stats
$3.75
$0.04(1.07%)
At close: 4:00 PM EDT
$3.75
$0.04(1.07%)
Day’s Range― - ―
52-Week Range$2.07 - $12.50
Previous CloseN/A
Volume1.09K
Average Volume (3M)3.06M
Market Cap
$14.99M
Enterprise Value-$332.89K
Total Cash (Recent Filing)$9.35M
Total Debt (Recent Filing)$331.00K
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 18, 2026EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding3,997,002
10 Day Avg. Volume1,756,841
30 Day Avg. Volume3,057,972
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-0.23
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$8.00Price Target Upside113.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$1.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained >90% gross margins indicate the SCD therapy has very low variable cost relative to price, enabling high incremental profitability as volumes scale. This margin profile supports long-term operating leverage, improves cash conversion once fixed costs are covered, and makes future scaling capital-efficient.
Early Commercial TractionConsistent hospital adoption and repeat orders show initial product-market fit in a specialist ICU niche. A growing installed base creates reference sites, clinical familiarity, and recurring procedure-driven demand, which are durable drivers of revenue expansion if the company continues adding centers and deepening usage per site.
Pivotal Trial Progress And FDA EngagementMaterial enrollment progress plus active regulatory dialogue reduces structural timing risk to market access. Advancing the pivotal and pursuing accelerated pathways (eg, modular PMA or Breakthrough mechanisms) can shorten approval timelines and unlock the much larger adult AKI market, permanently expanding the company’s addressable market.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow of ~-$13.7M TTM creates ongoing financing dependency. Without a material and sustained revenue ramp, the company will likely need external capital, which can dilute shareholders, limit strategic optionality, and constrain investments in commercialization or R&D over the medium term.
Very Small Absolute Revenue BaseDespite strong percentage growth, the underlying revenue run-rate is tiny, leaving operating losses large relative to sales. Reliance on low-volume pediatric cases limits near-term scale and makes fixed-cost absorption slow, requiring broader indications or adult market success to materially alter profitability dynamics.
Enrollment And Regulatory UncertaintyThe pivotal still requires substantial patient accrual and FDA outcomes are not assured. Delays or unfavorable regulatory feedback would postpone or block adult AKI approval, materially limiting TAM expansion and prolonging dependence on a narrow pediatric market, keeping long-term revenue and profitability uncertain.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $12.50 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $14.99M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Aug 18, 2026 which is in 22 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on May 13, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.825 by -$0.075.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.97.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 3,997,002 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.825. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear commercial and clinical momentum: notable YoY revenue growth (+69%), seven new hospital customers in Q1, completion of the SAVE Registry enrollment (50 patients), substantial trial progress (198/339 enrolled, ~58%) and a stronger cash position (+~79% YoY). Management emphasized high gross margins (>90%), disciplined operating spend and active FDA engagement on potential accelerated pathways. Offsetting this progress are the small absolute revenue base ($495k Q1), continued quarterly net losses (~$3.5M), dependence on ultra-rare pediatric case flow for adoption, ongoing enrollment and regulatory risks, and notable share dilution. Overall, the call presents meaningful early-stage commercial validation and clinical progress but also highlights typical execution and regulatory risks for a clinical-stage medical device company.View all ICU earnings summariesICU Stock 12 Month Forecast
Average Price Target
$8.00
▲(113.33% Upside)
Technical Analysis
Ownership Overview
3.79% Insiders
1.32% Mutual Funds
<0.01% Other Institutional Investors
93.99% Public Companies and
Individual Investors